Clinical Trials Logo

Autoimmune Diseases clinical trials

View clinical trials related to Autoimmune Diseases.

Filter by:

NCT ID: NCT04806113 Completed - Clinical trials for Rheumatoid Arthritis

COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases

COVIAAD
Start date: March 11, 2021
Phase: Phase 3
Study type: Interventional

This study will evaluate the Moderna RNA-based COVID-19 vaccine currently approved by Health Canada in people with rheumatic diseases. This study will help understand what the side effects of the vaccine in these patients are, and what is their capacity to develop antibodies that may confer protection from the COVID-19 disease.

NCT ID: NCT04805099 Completed - Autoimmune Diseases Clinical Trials

Checkpoint Inhibitors in Patients With Cancer and Underlying Autoimmune Disease

CIAD
Start date: November 1, 2020
Phase:
Study type: Observational

Patients with cancer and concurrent autoimmune diseases (AID) have been universally excluded from clinical trials evaluating immunotherapy. Data on the safety and efficacy of checkpoint inhibitors in patients with underlying AID is limited. The investigators performed a retrospective multicenter review of medical records of patients with diverse tumor types and underlying AID who received checkpoint inhibitors at Departments of Oncology, affiliated with the Hellenic Cooperative Oncology Group (HeCOG). The primary endpoint was progression-free survival (PFS).

NCT ID: NCT04754607 Completed - Autoimmune Diseases Clinical Trials

Effects of Low-Level Laser Therapy on Oxidative Stress Levels...

Start date: February 9, 2021
Phase: N/A
Study type: Interventional

Hashimoto's thyroiditis (HT) is the most commonly observed inflammatory and autoimmune disease of the thyroid gland. Many genetic and environmental factors play a role in the pathogenesis of the disease, including iodine exposure, drugs, chemicals, toxins, infections and smoking. In recent years, the relationship between oxidative stress level and thyroid autoantibodies in HT has attracted increasing attention of researchers. In the studies, it has been reported that oxidative stress levels may increase due to chronic inflammation, insufficient thyroid hormone levels, excessive autoimmune response and excessive iodine intake. Data from clinical studies clearly show that the balance between oxidants and antioxidants shifts towards the oxidative side in patients with autoimmune thyroiditis, suggesting that oxidative stress may be a key event in the pathophysiology of the disease, independent of thyroid function. Recent evidence has suggested that low-level laser therapy (LLLT) can improve thyroid function and reduce levels of thyroid peroxidase antibodies (TPOAb) in patients with hypothyroidism caused by chronic autoimmune thyroiditis. In the literature, data examining the effects of LLLT on oxidative stress level and quality of life in patients with HT is limited. As far as we know, it will be the first study examining the effect of LLLT on oxidative stress, fatigue and quality of life in cases diagnosed with HT. The aim of the study is to examine the effects of LT4 treatment combined with LLLT on thyroid autoimmunity, oxidative stress, fatigue and quality of life in patients with Hashimoto's diagnosis.

NCT ID: NCT04691232 Completed - Ulcerative Colitis Clinical Trials

Autologous Ex Vivo Expanded Regulatory T Cells in Ulcerative Colitis

Start date: February 22, 2021
Phase: Phase 1
Study type: Interventional

Together with Crohn's disease (CD), ulcerative colitis (UC) is one of the major forms of inflammatory bowel diseases (IBD).Currently, no curative therapy is available, since the pathophysiology of this disease is incompletely understood (1-3) and clinical practice demonstrates that current therapies induce remission in subgroups of patients only. Scientific evidence suggests that colitogenic immune responses can be controlled by increasing the number of circulating regulatory T cells (Treg) (4). The production of large numbers of autologous Treg is possible by isolation of CD25+ cells from the whole blood of a patient and subsequent ex vivo expansion in the presence of the immunomodulatory drug rapamycin, Interleukin-2 (IL-2) and CD3/CD28 expander beads (5). ER-TREG 01 is a single-center, open-label, fast-track phase I dose-escalation study designed to assess the safety profile and maximal tolerated dose (MTD) of a single infusion of ex vivo expanded autologous Treg in patients with active ulcerative colitis.

NCT ID: NCT04687332 Completed - Clinical trials for Neurological Autoimmune Diseases

IA or PE - What is the Best Treatment Option of Steroid Refractory Neurological Autoimmune Diseases

Start date: June 1, 2016
Phase: N/A
Study type: Interventional

In this prospective controlled monocentric observational study, we assessed safety and efficacy of therapy with IA or PE in patients with neurological autoimmune diseases. In the subgroup analysis of MS patients also the EDSS was evaluated. In addition, we investigated possible pathomechanisms, such as cytokine alterations under therapy.

NCT ID: NCT04665232 Completed - Infertility Clinical Trials

Immunomodulatory Effects of Subcutaneous Progesterone in Patients Affected by Autoimmune Diseases

Start date: April 2014
Phase:
Study type: Observational

This study evaluates the immunomodulatory effects of subcutaneous progesterone in patients undergoing IVF by determination of anti-nuclear antibodies (ANA),extractable nuclear antigen antibodies (ENA),anti- neutrophil cytoplasmic antibodies(ANCA),anti-DNA antibodies, anti-cardiolipin antibodies (ACA),Lupus anticoagulant antibodies (LAC) and C3 and C4 fractions of complement on the day of beta hCG dosage and during the eigth week of gestation.

NCT ID: NCT04591470 Completed - Clinical trials for Male Infertility Due to Antisperm Antibody

Influence of Inguinal Hernia Repair on Sperm Autoimmunity

SPERMAR
Start date: June 1, 2020
Phase:
Study type: Observational

Influence of inguinal hernia repair on sperm autoimmunity using MAR test

NCT ID: NCT04473742 Completed - Clinical trials for Positive Testing for ANA as a Marker of Systemic Autoimmune Diseases

Effects of Silica and Asbestos Fibres on the Efferocytosis Capacities of Macrophages

MacFibOsis
Start date: March 31, 2021
Phase: N/A
Study type: Interventional

Evaluation of the efferocytosis capacities of blood Monocyte Derived Macrophages (MDM) from patients with a history of asbestosis or silica exposure and comparison of these capacities with those of MDM from healthy donors.

NCT ID: NCT04345159 Completed - Clinical trials for Rheumatoid Arthritis

Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease

COVCALL
Start date: April 17, 2020
Phase:
Study type: Observational

This epidemiological, transversal, cohort study aims to determine the potential influence of an active long-term hydroxychloroquine intake over the prevalence of a history of symptoms evocative of a COVID-19 infection in patients with a history of systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome or psoriatic arthritis, during the epidemic period in France. The information is gathered using a standardized questionnaire, by phone call.

NCT ID: NCT04298749 Completed - Autoimmune Diseases Clinical Trials

Safety and Tolerability of GX-P1 in Healthy Male Volunteers

Start date: August 11, 2020
Phase: Phase 1
Study type: Interventional

This study is a single-center, double-blind, placebo-controlled, phase I study with healthy male volunteers receiving ascending single dose of GX-P1